Recent advancements in pharmaceuticals for treating obesity, such as glucagon like peptide-1 (GLP-1) receptor agonists, have attracted massive interest due to the ubiquitous nature of the obesity epidemic (Jastreboff and Kushner, 2023; Knudsen and Lau, 2019; Torekov et al., 2011). This evidence concerns the gene GCG and obesity disorder.